New Jersey S4222 aims to improve access to lower-cost generic and biosimilar drugs.
New Jersey S4222 seeks to enhance access to lower-cost generic and biosimilar drugs by requiring managed care organizations and vendors to prioritize these drugs in their formularies. The bill mandates that if a biosimilar is available, it should be prescribed to enrollees who have not previously been treated with the prescribed brand drug. Additionally, it requires that generic and biosimilar drugs with lower wholesale acquisition costs be placed on formularies with more favorable cost-sharing terms.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.